Epeius Biotechnologies Corporation, San Marino, CA 91108, USA.
Int J Oncol. 2010 Jun;36(6):1341-53. doi: 10.3892/ijo_00000619.
The advent of pathotropic (disease-seeking) targeting technology has ushered cancer gene therapy across the threshold of history, marking the beginning of a new epoch of medical praxis. For the first time, clinical oncologists can reach beyond the finest of catheters, beyond the reach of the most gifted surgeons, to the very fabric of metastatic disease in an effort to halt the progression and turn the tide of otherwise intractable cancers. The enabling molecular biotechnologies embodied in the leading tumor-targeted agent, Rexin-G, and its timely development as a safe and effective anti-cancer drug - from oncogene discovery and target validation, to molecular engineering of the core nanotechnologies, to the first clinical proofs-of principle, confirmatory trials, expanded access programs, and accelerated regulatory approvals - have been extensively documented in the medical literature. Therefore, this paper represents a final chapter, highlighting a series of noteworthy cases studies in the emergent field of targeted genetic medicine: case studies which, in and of themselves, reveal vital and important aspects of the molecular-genetic bio-pharmacology, advanced clinical protocols, refinement of patient monitoring, expanding treatment options, and strategic medical approaches to patient care that exemplify and thereby extend the established principles of pathotropic targeting and cancer gene therapy to a new generation of clinical practitioners.
靶向（疾病）技术的出现使癌症基因治疗跨越了历史的门槛，标志着医学实践新纪元的开始。临床肿瘤学家首次能够超越最精细的导管，超越最有天赋的外科医生的能力范围，深入转移性疾病的核心，努力阻止其进展并扭转 otherwise intractable 癌症的局面。以 Rexin-G 为代表的领先肿瘤靶向药物所体现的使能分子生物技术及其作为安全有效的抗癌药物的及时开发——从癌基因发现和靶点验证，到核心纳米技术的分子工程，再到首次临床原理验证、确证性试验、扩大准入计划和加速监管审批——在医学文献中都有广泛的记载。因此，本文代表了靶向基因医学这一新兴领域的最后一章，重点介绍了一系列值得注意的案例研究：这些案例研究本身揭示了分子遗传生物药理学、先进临床方案、患者监测的精细化、治疗选择的扩大以及战略医疗方法等方面的重要方面，这些方面体现并扩展了靶向治疗和癌症基因治疗的既定原则，为新一代临床医生提供了指导。
